On October 25, 2023 Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, reported that the company plans to report new and updated data from its ongoing phase 2a study with the candidate drug fostrox in combination with Lenvima in advanced hepatocellular carcinoma (HCC) (Press release, Medivir, OCT 25, 2023, View Source [SID1234636346]). The data will focus on the 18 out of 21 total patients that have had a minimum follow-up of 12 weeks.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The data update will be part of Medivir’s interim report for the third quarter on Friday, October 27, 2023, followed by a comprehensive update in a webcasted presentation with associated slide presentation at 14.00 CET the same day.
In the webcast, Medivir will provide further context about how these data increase the opportunity for fostrox + Lenvima to transform treatment of second line HCC, a population for whom there are no approved medical treatments post current standard of care. In addition, the company will outline how promising clinical benefit in a high unmet medical need second line HCC population, opens the possibility for a faster path to approval and its commercial opportunity.
The webcast will be hosted by Medivir’s CEO Jens Lindberg together with Magnus Christensen, CFO, Dr. Pia Baumann, CMO, and Fredrik Öberg, CSO, who are joined in the presentation by Dr. Jeff Evans, who is an investigator in the fostrox clinical development program and a member of Medivir’s Scientific Advisory Council. All presenters will be available to answer questions following the formal presentations.
To access the webcast and information about the teleconference, please click HERE!
The webcast will also be streamed via a link on the website: www.medivir.com/investors/calendar
The presentation will be available on Medivir’s website after the webcast.